Kinevant Sciences GmbH
4 clinical trials · Sponsor
◉ Watch Kinevant Sciences GmbH
| Record | Firm | Date |
|---|---|---|
| A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis (NCT05314517) | Kinevant Sciences GmbH | 2022-08-31 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis (NCT05351554) | Kinevant Sciences GmbH | 2022-08-23 |
| A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) (NCT04351243) | Kinevant Sciences GmbH | 2020-04-15 |
| Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis (NCT04205851) | Kinevant Sciences GmbH | 2019-11-12 |
Track Kinevant Sciences GmbH automatically
Every clearance here is in the API, with alerts when new ones post.